Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TLACAELEL: Switching to DTG/3TC in Virologically Suppressed HIV
NCT07138144Phase 4Recruiting
- Start
- Jul 2025
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of dolutegravir, lamivudine in human immunodeficiency virus infection (HIV). Started Jul 2025; status: recruiting.
02
Drugs
dolutegravirlamivudine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT07138144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07138144.